William Blair believes investors could view Viking Therapeutics (VKTX)’ multi-year manufacturing pact with CordenPharma as a negative to ...
Pharmaceutical Technology on MSN9d
Viking strikes $150m deal to secure supply of obesity drugViking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
In exchange for securing these dedicated production capabilities, Viking will prepay $150 million between 2025 and 2028, which will be credited against future supply orders. The company retains ...
Both Novo Nordisk and Eli Lilly have faced significant supply ... receptor. Viking is testing VK2735 in two formulations, a subcutaneous injection and an oral pill. The company expects to launch ...
SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ: VKTX), currently valued at $3.14 billion, has entered into a strategic manufacturing agreement with CordenPharma to ensure a steady supply of its VK2735 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results